knowledge -WSS

knowledge

author：explore 2025-09-03 05:32:22 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

This week, an encouraging turnaround for Ocular Therapeutix, a chat with Alnylam’s CEO defending changes to the HELIOS-B study and talking up its hypertension treatment, and quick takes on Amylyx and obesity stocks.

A Worst CEO gets some much-needed help

For most of last year, Ocular Therapeutix CEO Antony Mattessich promised shareholders that he was close to nailing down a lucrative pharma partnership that would pay for late-stage clinical trials of the company’s treatments for degenerative eye diseases. The deal never happened. I heard from many Ocular investors who were frustrated and angry about Mattesich’s poor job performance. He ended up earning a spot last year on my worst biopharma CEO list. It was an easy pick.

On Thursday, Ocular announced a meaningful “leadership update.” Mattessich is still the CEO, but let’s just say the company’s board decided to surround him with new executives and retinal experts with proven track records of getting stuff done.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Cord blood banking comes at a high cost to babies

WSS

Hospitals need to get ahead of regulations on climate change

Congress: Prevent baby formula shortages by passing a new bill

Stroke rates rising, especially in working

Medical students need to learn the potent medicine of empathy

Decentralized clinical trials need collaboration to achieve wider use

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

explore

knowledge

A Worst CEO gets some much-needed help

Wikipedia

Medicare details structure of new drug price negotiation program

Should insurance cover cosmetic surgery?

Peter Hotez and the public health issue of online harassment

Ozempic cut risk of death in diabetes patients with chronic kidney disease

Heart attack and stroke risk calculators need revising

ASCO: AstraZeneca's hat trick, and palliative care's spotlight

ChatGPT in medicine: STAT answers readers' burning questions

Bubonic plague hit France in 1720. Officials dithered. Sound familiar?

United colonoscopy coverage change 'may cost lives,' doctors say

The world needs the new pandemic treaty

hotspot

ASCO: AstraZeneca says CAR

Woman returns to dialysis after doctors remove transplanted pig kidney

Innovation in antibiotics is ailing. 'Brain drain' may kill it

Clinicians often fail to acknowledge the pain caused by long Covid

ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

Pharma’s losing bet in New Jersey

hotspot

hotspot

hotspot

hotspot